Abbott is expanding its contract bio-manufacturing capabilities. The company recently qualified and launched a manufacturing suite in Worcester, MA containing 2 x 500 L single-use bioreactors. According to the company, this additional early phase cGMP capacity capitalizes on disposable technologies to optimize production value in terms of process flexibility and efficient change over.

Abbott has also introduced a new chemically defined media, which, according to the company, has demonstrated titer improvements by as much as 30% compared to prior generation media compositions.